The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Can anyone find the publication of the supplementary prospectus on the NSF website or Morning Star? I can't see it there, should be at midday...
https://www.investegate.co.uk/non-standard-fin--nsf-/rns/publication---posting-of-supplementary-prospectus/201905281356213621A/
IMO there's no sign the share price has turned because the spread has been such that buys are being shown as sells constantly so the signals will be wonky IMO.
All I would advise to anyone is to study the buys and sells and get a few quotes for yourself (you do not have to accept, you can decline) to see what the numbers actually are being offered and not what is being "shown" by the system which is quite often very misleading IMO.
Don't believe all what you see/hear - DYOR.
at these levels each day after 4.30 24-May-1916:36:02 - 63.23k & several 23.63k buys, reckon that's why the price is low, for certain folk to get a good price, once they have their fill, we will be off.
Talking it down for a good entry for yourself means someone else is losing out, not a good trait IMO. If you want in (which is obviously why people are watching, just buy some!). IMO.
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, is pleased to announce the appointment of Dr John Chiplin as Non-Executive Chairman of the Company, and the appointment of Dr Chris Britten as a Non-Executive Director of the Company (the "Appointments"). In addition, Paul Titley has decided to step down from the board for personal reasons and Dr David Templeton, formerly Chairman, will now serve as a part-time Executive Director in order to manage the technical aspects of the Company's Nuvec® programme. All board changes are effective immediately.
https://www.investegate.co.uk/n4-pharma-plc--n4p-/rns/board-changes/201905210700256256Z/
So has Coco the Clown left the building or was he the sacrificial lamb to try and please shareholders?
PFG shares are cheap to buy at the (IMO) for both new investors and current holders to average down.
Hope the board issues some real share boosting news n the morning, be fun to watch them all dive back in..
would be welcomed here, board!
The primary aim of this drill program was to advance @G11Res 'Big Think' exploration strategy by providing 3D geological information ahead of an anticipated 'Big Drill' exploration program later this year
https://buff.ly/2LrJhGK
The primary aim of this drill program was to advance @G11Res 'Big Think' exploration strategy by providing 3D geological information ahead of an anticipated 'Big Drill' exploration program later this year
https://buff.ly/2LrJhGK
"The identification of a new hydrothermal system of the scale observed in the southern part of the Stonepark #Zinc Project is very exciting news". #ARK Patrick Cullen: "This area of Limerick hosts the two largest undeveloped zinc deposits in Ireland, at Stonepark and at Pallas Green, in a region recognised for its world class zinc mines and zinc grades".
Taken from Twitter yesterday.
Arkle Resources PLC? @ArkleResources · May 7
? More
Arkle Resources PLC Retweeted Arkle Resources PLC
• Hole G11-450-02 intersected a 230 metre thick hydrothermal system displaying abundant sulphide mineralisation with elevated #Zinc
• The outer margin of a potential new Irish-Type zinc system has been identified 10 kilometres southeast of Glencore's Pallas Green deposit
Significant New Mineralisation along Pallas Green Corridor at #Stonepark #Zinc Project along Pallas Green Corridor at Stonepark Zinc Project
Arkle Resources PLC (LON: ARK), the Irish gold and zinc exploration and development company, is pleased to report results from the preliminary drill program at the Stonepark Zinc Project located in Limerick, Ireland. The Stonepark Zinc Project is a joint venture with Group Eleven Resources Corp. ("Group Eleven"). Arkle holds a 23.44% interest.
https://m.londonstockexchange.com/exchange/mobile/news/detail/14065063.html
There was surely a contract, it either stated/detailed the terms (dose etc) and UoA dropped the ball (and should offer a free replacement trial and apologise for total incompetence), or N4P didn't instruct them precisely enough surely? and should own up to it IMO
Either way it was totally unprofessional and shareholders are expected to pay the price for incompetence which is wrong - someone should be held accountable, this is a serious business that needs total accuracy. It shouldn't just be accepted.
again this morning by MMs - it was 2.14 to sell so when 2.20 - 2.30 the 2.20's were buys - how are they allowed to mislead (imo) the ramge so badly? Try it in a retail shop and you'll be fined / Trading Standards would be involved - needs looking at IMO?